Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential January 1, 2019 J Clin Aesthet Dermatol. 2019;12(1):11–15 by James Q. Del Rosso, DO; Leon CONTINUE READING »
Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream November 1, 2018 J Clin Aesthet Dermatol. 2018;11(11):15–19 by Neal D. Bhatia, MD; David M. CONTINUE READING »
